在抗PD-1治疗失败后,皮肤状细胞癌患者的进展模式和临床结果
K Khaddour1, P Kote1, M Liu1
1Dana-Farber Cancer Institute, Boston, USA.
ESMO open
|March 12, 2026
概括
在晚期皮肤状细胞癌 (CSCC) 中抗编程细胞死亡蛋白1 (PD-1) 治疗失败后的结果显示,远程转移和局域性进展是常见的. 较低的瘤突变负担 (TMB) 与初级耐药性有关,而先前的化疗预测生存率较差.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 皮肤病学 皮肤病学
背景情况:
- 反编程细胞死亡蛋白1 (PD-1) 疗法是晚期皮肤状细胞癌 (CSCC) 的标准治疗方法.
- 治疗失败发生在很大一部分患者身上,对失败后的治疗结果的数据有限.
- 本研究研究了抗PD-1治疗失败后CSCC患者的进展模式和临床结果.
研究的目的:
- 为了研究在先进的CSCC中抗PD-1治疗失败后疾病进展的模式.
- 为了确定抗PD-1治疗失败后CSCC患者的临床结果和预后因素.
- 在这个患者群体中评估后续治疗的疗效.
主要方法:
- 对接受抗PD-1治疗的CSCC患者的回顾性分析.
- 评估临床病理特征和生存结果 (整体生存和无事件生存).
- 卡普兰-梅尔生存估计方法和多变量回归用于预后因素识别.
主要成果:
- 远程转移性 (42%) 和局域性 (37%) 进展是抗PD-1失败后最常见的模式.
- 在62.5%的患者中观察到初级耐药性,与明显较低的瘤突变负担 (TMB) 相关.
- 随后的治疗,包括 cetuximab 和局部疗法,在选择的患者中显示出反应;之前的化疗与较差的整体存活率有关.
结论:
- 远程转移和局域性进展是CSCC中抗PD-1失败后的关键模式.
- 较低的TMB与抗PD-1治疗的初级耐药性有关.
- 之前的化疗对整体存活率产生负面影响,而一些患者从随后的治疗中受益,如 cetuximab 和局部治疗.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.4K
相关概念视频
Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Skin Cancer
6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K
Cancer Survival Analysis
811
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
811
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
